The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Oncol.
Sec. Thoracic Oncology
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1414900
This article is part of the Research Topic Biomarker-Guided Strategies in NSCLC Immunotherapy View all articles
PD-1 expression in tumor infiltrating lymphocytes as a prognostic marker in early-stage non-small cell lung cancer
Provisionally accepted- 1 Thoracic Oncology Center, Department of Oncology, Karolinska University Hospital, Stockholm, Stockholm, Sweden
- 2 Department of Oncology-Pathology, Karolinska Institutet (KI), Stockholm, Stockholm, Sweden
- 3 Division of Pathology, Department of Laboratory Medicine, Karolinska Institutet (KI), Huddinge, Stockholm, Sweden
- 4 Department of Clinical Pathology and Cytology, Karolinska University Hospital, Huddinge, Sweden
- 5 Department of Cellular Pathology, Royal Liverpool University Hospital, Liverpool, United Kingdom
- 6 Department of Thoracic Surgery, University of Valencia, Valencia, Valencian Community, Spain
Introduction: Programmed death ligand -1 (PD-L1) expression is a well-established predictive biomarker for immunotherapy in non-small cell lung cancer (NSCLC). Programmed death -1 (PD-1) serves as the target protein to PD-L1 and their interaction serves as a crucial pathway for immune evasion. This study aimed to investigate the expression pattern of PD-1 on Tumor-infiltrating lymphocytes (TILs) in early-stage NSCLC, and its potential role as prognostic biomarker.Materials & Methods: PD-1 was evaluated in 474 surgical resected early-stage NSCLC specimens, using Tissue microarray and immunohistochemical staining. Expression was scored as negative (<1%) or positive. Positive PD-1 expression was further divided into low (<10%) and high (≥10%). None of the patients had received treatment with PD-1/PD-L1 inhibitors.Results: PD-1 expression ≥1% in TILs was observed in 83.5% of cases and was associated with pT stage (p=0.02), grade 3 (p=0.004), and adenocarcinoma subtype (p=0.05). Individuals with high PD-1 expression (≥10%) experienced reduced 10-year overall survival (Log-Rank test = 0.005). In addition, high PD-1 expression emerged as an independent factor associated with reduced survival on multivariate analysis (HR: 1.328 (95% CI: 1.074-1.641). Conclusions: Patients with early-stage NSCLC who exhibited PD-1 expression of ≥10% on TILs had an unfavorable 10-year OS rate. These findings indicate that elevated PD-1 expression on TILs can be associated with immune evasion during the early stages of malignancy evolution in the NSCLC setting and further research is required to further delineate the role of PD-1/PD-L1 pathway on tumor immune senescence. These results underline the potential role of PD-1/PD-L1 inhibitors in the treatment of early-stage NSCLC.
Keywords: Early-stage NSCLC, TILs, PD-1, prognosis, Immunotherapy
Received: 09 Apr 2024; Accepted: 09 Sep 2024.
Copyright: © 2024 Dan, Aricak, Rounis, Montero-Fernandez, Guijarro, Ekman, Ortiz-Villalón and De Petris. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Asaf Dan, Thoracic Oncology Center, Department of Oncology, Karolinska University Hospital, Stockholm, Stockholm, Sweden
Luigi De Petris, Department of Oncology-Pathology, Karolinska Institutet (KI), Stockholm, 171 76, Stockholm, Sweden
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.